Trial results

Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

NCT07487103 on ClinicalTrials.gov · last registry update 2026-04-28

Registered but not yet open, with 478 participants planned. Due to report December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change in HbA1c. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Qilu Pharmaceutical Co., Ltd.

Sponsor type

Industry

Enrollment

478

Started

2026-05-01

Primary completion

2026-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.